Development and Validation of a Clinical Risk Score for Intensive Care Resource Utilization After Colon Cancer Surgery: a Practical Guide to the Selection of Patients During COVID-19.


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
01 2021
Historique:
received: 23 04 2020
accepted: 25 05 2020
pubmed: 5 6 2020
medline: 13 2 2021
entrez: 5 6 2020
Statut: ppublish

Résumé

The purpose of this study was to develop and validate a prediction model and clinical risk score for Intensive Care Resource Utilization after colon cancer surgery. Adult (≥ 18 years old) patients from the 2012 to 2018 ACS-NSQIP colectomy-targeted database who underwent elective colon cancer surgery were identified. A prediction model for 30-day postoperative Intensive Care Resource Utilization was developed and transformed into a clinical risk score based on the regression coefficients. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) and Hosmer-Lemeshow goodness-of-fit test. The model was validated in a separate test set of similar patients. In total, 54,893 patients underwent an elective colon cancer resection, of which 1224 (2.2%) required postoperative Intensive Care Resource Utilization. The final prediction model retained six variables: age (≥ 70; OR 1.90, 95% CI 1.68-2.14), sex (male; OR 1.73, 95% CI 1.54-1.95), American Society of Anesthesiologists score (III/IV; OR 2.52, 95% CI 2.15-2.95), cardiorespiratory disease (yes; OR 2.22, 95% CI 1.94-2.53), functional status (dependent; OR 2.81, 95% CI 2.22-3.56), and operative approach (open surgery; OR 1.70, 95% CI 1.51-1.93). The model demonstrated good discrimination (AUC = 0.73). A clinical risk score was developed, and the risk of requiring postoperative Intensive Care Resource Utilization ranged from 0.03 (0 points) to 19.0% (8 points). The model performed well on test set validation (AUC = 0.73). A prediction model and clinical risk score for postoperative Intensive Care Resource Utilization after colon cancer surgery was developed and validated.

Sections du résumé

BACKGROUND
The purpose of this study was to develop and validate a prediction model and clinical risk score for Intensive Care Resource Utilization after colon cancer surgery.
METHODS
Adult (≥ 18 years old) patients from the 2012 to 2018 ACS-NSQIP colectomy-targeted database who underwent elective colon cancer surgery were identified. A prediction model for 30-day postoperative Intensive Care Resource Utilization was developed and transformed into a clinical risk score based on the regression coefficients. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) and Hosmer-Lemeshow goodness-of-fit test. The model was validated in a separate test set of similar patients.
RESULTS
In total, 54,893 patients underwent an elective colon cancer resection, of which 1224 (2.2%) required postoperative Intensive Care Resource Utilization. The final prediction model retained six variables: age (≥ 70; OR 1.90, 95% CI 1.68-2.14), sex (male; OR 1.73, 95% CI 1.54-1.95), American Society of Anesthesiologists score (III/IV; OR 2.52, 95% CI 2.15-2.95), cardiorespiratory disease (yes; OR 2.22, 95% CI 1.94-2.53), functional status (dependent; OR 2.81, 95% CI 2.22-3.56), and operative approach (open surgery; OR 1.70, 95% CI 1.51-1.93). The model demonstrated good discrimination (AUC = 0.73). A clinical risk score was developed, and the risk of requiring postoperative Intensive Care Resource Utilization ranged from 0.03 (0 points) to 19.0% (8 points). The model performed well on test set validation (AUC = 0.73).
CONCLUSION
A prediction model and clinical risk score for postoperative Intensive Care Resource Utilization after colon cancer surgery was developed and validated.

Identifiants

pubmed: 32495141
doi: 10.1007/s11605-020-04665-9
pii: 10.1007/s11605-020-04665-9
pmc: PMC7269615
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-259

Références

J Hosp Infect. 2020 Jun;105(2):113-115
pubmed: 32294511
Intensive Care Med. 2018 Sep;44(9):1427-1435
pubmed: 30054691
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Am Coll Surg. 2020 Aug;231(2):281-288
pubmed: 32278725
J Surg Res. 2020 Mar;247:180-189
pubmed: 31753556
J Clin Epidemiol. 2015 Feb;68(2):134-43
pubmed: 25579640
J Am Coll Surg. 2020 Jun;230(6):1080-1091.e3
pubmed: 32240770
J Am Coll Surg. 2010 Jan;210(1):6-16
pubmed: 20123325
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Ann Surg. 2021 Dec 1;274(6):1025-1031
pubmed: 31850985
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
BMC Med Res Methodol. 2014 Mar 19;14:40
pubmed: 24645774
Br J Surg. 2019 Sep;106(10):1298-1310
pubmed: 31216064
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538

Auteurs

Richard Garfinkle (R)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Maria Abou-Khalil (M)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Ebram Salama (E)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Daniel Marinescu (D)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Allison Pang (A)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Nancy Morin (N)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Sebastian Demyttenaere (S)

Department of Surgery, St. Mary's Hospital, Montreal, QC, Canada.

A Sender Liberman (AS)

Department of Surgery, McGill University Health Center, Montreal, QC, Canada.

Carol-Ann Vasilevsky (CA)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada.

Marylise Boutros (M)

Division of Colon and Rectal Surgery, Jewish General Hospital, Montreal, QC, Canada. mboutros@jgh.mcgill.ca.
McGill University, Jewish General Hospital, 3755 Cote Ste Catherine, G-317, Montreal, Quebec, H3T 1E2, Canada. mboutros@jgh.mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH